Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 proof-of-concept trial of NNC0114-0006 and liraglutide for preservation of beta-cell function in newly diagnosed adult type 1 diabetes
MOH_2017-06-22_000475Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2015
- Modality
- Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NNC0114-0000-0005 and liraglutide in diabetes mellitus type 1 (T1D) (4 arms), sponsored by Novo Nordisk. Started Jun 2015; status: completed.
02
Drugs
NNC0114-0000-0005liraglutide
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on MOH_2017-06-22_000475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-22_000475.